Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mesenchymal stromal cells (Post Graduate Institute of Medical Education and Research)
- Development stage
- Unknown
- Lead developer
- Post Graduate Institute of Medical Education and Research
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial
01
Overview
**Autologous bone marrow-derived mesenchymal stromal cells** are an investigational, patient-specific cell therapy developed by Post Graduate Institute of Medical Education and Research for insulin-requiring type 2 diabetes mellitus. Bone marrow is aspirated from each patient, mononuclear cells are isolated and cultured to expand the adherent mesenchymal stromal-cell population, and the resulting cells are delivered by targeted infusion into the superior pancreaticoduodenal artery. The proposed activity is regenerative and paracrine rather than receptor-specific: the cells are intended to improve the pancreatic microenvironment, promote angiogenic and trophic signaling, support residual beta-cell function, and improve insulin sensitivity. In the randomized controlled study, this MSC intervention was evaluated separately from autologous bone marrow-derived mononuclear cells and sham treatment.
- Other names
- autologous bone marrow-derived mesenchymal stem cellsABM-MSCs
Beyond the preview
Go deeper on autologous bone marrow-derived mesenchymal stromal cells (Post Graduate Institute of Medical Education and Research).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stromal cells (Post Graduate Institute of Medical Education and Research).